Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.73 |
| ▸ | F2 | P00734 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056229 | 0.92 | F10 (0.62) | F10F2 | |
| SCHEMBL12833684 | 0.91 | F10 (0.76) | F10F2 | |
| SCHEMBL1252670 | 0.90 | F10 (0.76) | F10F2 | |
| SCHEMBL12507540 | 0.89 | F10 (0.79) | F10F2 | |
| SCHEMBL12507958 | 0.89 | F10 (0.78) | F10F2 | |
| SCHEMBL13631342 | 0.88 | F10 (0.82) | F10F2 | |
| SCHEMBL1252824 | 0.88 | F10 (0.76) | F10F2 | |
| SCHEMBL1252703 | 0.87 | F10 (0.92) | F10F2 | |
| SCHEMBL12507968 | 0.87 | F10 (0.83) | F10F2 | |
| SCHEMBL1321668 | 0.86 | F10 (0.83) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | F10 196/4885F2 4/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | F10 127/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.